• Product nameAnti-SHP2 (phospho Y542) antibody
    See all SHP2 primary antibodies
  • Description
    Rabbit polyclonal to SHP2 (phospho Y542)
  • SpecificityThis antibody is specific for SHP2 phosphorylated at tyrosine 542.
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat
    Predicted to work with: Human
  • Immunogen

    Synthetic phosphopeptide derived from the region of human SHP2 that contains tyrosine 542. The sequence is conserved in mouse, rat and chicken.

  • Positive control
    • NIH3T3 cells treated with PDGF.


  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C long term.
  • Storage bufferPreservative: 0.05% Sodium Azide
    Constituents: 50% Glycerol, PBS, 1mg/ml BSA. pH 7.3
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Purification notesPurified from rabbit serum by sequential epitope-specific chromatography. The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated SHP2. The final product is generated by affinity chromatography using a SHP2 derived peptide that is phosphorylated at tyrosine 542.
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas


Our Abpromise guarantee covers the use of ab17939 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesWB: 1/1000. Detects a band of approximately 70 kDa.
    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionActs downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus.
    • Tissue specificityWidely expressed, with highest levels in heart, brain, and skeletal muscle.
    • Involvement in diseaseDefects in PTPN11 are the cause of LEOPARD syndrome type 1 (LEOPARD1) [MIM:151100]. It is an autosomal dominant disorder allelic with Noonan syndrome. The acronym LEOPARD stands for lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and deafness.
      Defects in PTPN11 are the cause of Noonan syndrome type 1 (NS1) [MIM:163950]. Noonan syndrome (NS) is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis. Some patients with Noonan syndrome type 1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villomoduolar synovitis (PVNS) when occurring in the jaw or joints. Note=Mutations in PTPN11 account for more than 50% of the cases. Rarely, NS is associated with juvenile myelomonocytic leukemia (JMML). NS1 inheritance is autosomal dominant.
      Defects in PTPN11 are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia. It is characterized by leukocytosis with tissue infiltration and in vitro hypersensitivity of myeloid progenitors to granulocyte-macrophage colony stimulating factor.
      Defects in PTPN11 are a cause of metachondromatosis (MC) [MIM:156250]. It is a skeletal disorder with radiologic fetarures of both multiple exostoses and Ollier disease, characterized by the presence of multiple enchondromas and osteochondroma-like lesions.
    • Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Non-receptor class 2 subfamily.
      Contains 2 SH2 domains.
      Contains 1 tyrosine-protein phosphatase domain.
    • DomainThe SH2 domains repress phosphatase activity. Binding of these domains to phosphotyrosine-containing proteins relieves this auto-inhibition, possibly by inducing a conformational change in the enzyme.
    • Post-translational
      Phosphorylated on Tyr-546 and Tyr-584 upon receptor protein tyrosine kinase activation; which creates a binding site for GRB2 and other SH2-containing proteins.
    • Cellular localizationCytoplasm.
    • Information by UniProt
    • Database links
    • Alternative names
      • BPTP3 antibody
      • CFC antibody
      • JMML antibody
      • METCDS antibody
      • MGC14433 antibody
      • NS1 antibody
      • OTTHUMP00000166107 antibody
      • OTTHUMP00000166108 antibody
      • Protein tyrosine phosphatase 2 antibody
      • Protein tyrosine phosphatase 2C antibody
      • Protein tyrosine phosphatase non receptor type 11 antibody
      • Protein-tyrosine phosphatase 1D antibody
      • Protein-tyrosine phosphatase 2C antibody
      • PTN11_HUMAN antibody
      • PTP-1D antibody
      • PTP-2C antibody
      • PTP1D antibody
      • PTP2C antibody
      • PTPN11 antibody
      • SAP2 antibody
      • SH-PTP2 antibody
      • SH-PTP3 antibody
      • SH2 domain containing protein tyrosine phosphatase 2 antibody
      • SHP 2 antibody
      • SHP-2 antibody
      • Shp2 antibody
      • SHPTP2 antibody
      • SHPTP3 antibody
      • Syp antibody
      • Tyrosine-protein phosphatase non-receptor type 11 antibody
      see all

    Anti-SHP2 (phospho Y542) antibody images

    • Predicted band size : 70 kDa

      Western blot using ab17939 on 10-30µg NIH3T3 cell lysate.

      Lane 1: untreated cells.
      Lane 2: cells treated with PDGF.
      Lane 3: cells treated with PDGF. Antibody blocked with non-phosphorylated immunopeptide.
      Lane 4: cells treated with PDGF. Antibody blocked with a generic tyrosine-phosphorylated peptide.
      Lane 5: cells treated with PDGF. Antibody blocked with phosphorylated immunopeptide.

    References for Anti-SHP2 (phospho Y542) antibody (ab17939)

    This product has been referenced in:
    • Svensson KJ  et al. Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1. J Biol Chem 288:17713-24 (2013). Read more (PubMed: 23653359) »
    • Banes-Berceli AK  et al. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am J Physiol Heart Circ Physiol 293:H1291-9 (2007). WB ; Rat . Read more (PubMed: 17526654) »

    See all 2 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab17939.
    Please use the links above to contact us or submit feedback about this product.